45. Montoliu, C. et al. Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients. J. Mol. Med. 2007;85, 237-45
46. Stewart, C. A., Malinchoc, M., Kim, W. R. & Kamath, P S. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007;13, 1366-71
47. Albrecht, J. Cyclic GMP in blood and minimal hepatic encephalopathy: fine-tuning of the diagnosis. J. Mol. Med.2007; 85, 203-5
48. Marchesini, G., Fabbri, A., Bianchi, G., Brizi, M. & Zoli, M. Zinc
49. Sushma, S. et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology.1992; 16, 138-44
50. Kircheis, G. et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology.1997; 25, 1351-60
51. Kircheis, G., Wettstein, M., Dahl, S. & Häussinger, D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab. Brain Dis.2002; 17, 453-62